China NT Pharma's Hong Kong IPO Could Trigger Consolidation In Distribution Sector
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector
You may also be interested in...
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms
China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector